Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

72.0/100
Buy Not Halal Healthcare
Price $955.47
Market Cap $98.82B
52-Week Change +37.48%

Is REGN a good investment?

Regeneron Pharmaceuticals, Inc. (REGN) has a Plutrex AI rating of 72.0/100 as of November 04, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Elite profitability moat: 82.7% gross margin, 40.5% operating margin, 28.5% net margin — operating margin 125 percentage points above deeply negative industry average; Q3 2026 Non-GAAP EPS surged 70% YoY to $20.07, demonstrating accelerating operational leverage from Dupixent, EYLEA HD, and LIBTAYO growth engines. Main concern: Stock price of $973.36 is 8.8% ABOVE the analyst consensus target of $894.25 — after analysts JUST revised targets upward post-Q3 beat; this is the dominant near-term risk; risk/reward math is broken: upside to analyst target = -$79.11 (-8.1%), downside to any reasonable stop (~$900-$920) = -$53-$73, meaning new buyers face negative expected value at current price regardless of quality.

Investment Summary

Regeneron Pharmaceuticals (REGN) is a world-class biotech franchise — elite 82.7% gross margin, 40.5% operating margin, virtually debt-free (D/E 0.06), $9.3B cash fortress, and $3.6B annual FCF — but the stock at $973.36 has appreciated 20.5% since our prior analysis and now trades 8.8% ABOVE the analyst consensus target of $894.25, creating a structurally unfavorable risk/reward. The Q3 2026 earnings print was exceptional (Non-GAAP EPS +70% YoY to $20.07, driven by Dupixent, EYLEA HD, and LIBTAYO), and analysts are revising estimates upward. However, the PEG of 1.04 on the 5-year growth view looks attractive until you apply the near-term lens: next-year EPS growth of only 4.1% implies a forward PEG of ~5.2x. The P/E of 21.49x is reasonable in isolation but the analyst community — which has just raised estimates — still sees -8.8% downside to $894.25. The stock has run hard on a great quarter and sentiment (96.3/100 news score) is near peak optimism. A fantastic company at a currently disadvantageous entry price.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
93/100
Growth Potential
52/100
Valuation
42/100
Profitability
94/100
Debt Management
95/100
Analyst Sentiment
40/100
Technical Momentum
68/100
Insider Confidence
45/100
News Sentiment
90/100

Fundamental Analysis

Profitability is exceptional across every metric: gross margin 82.7% (vs industry avg 80.5%), operating margin 40.5% (vs industry average of -84.6% — a 125 percentage point advantage), net margin 28.5% (vs industry avg 0.43%, approximately 66x superior), ROE 14.9% (vs industry avg -2.8%). P/E of 21.49x represents a 21.5% discount to biotech peers averaging 27.37x, and PEG of 1.04 is 52.7% below the industry average PEG of 2.20 — on the surface, a quality-at-discount story. Financial health is fortress-grade: D/E of 0.06 vs industry 0.23 (73.9% less leveraged), $9.3B cash, $3.588B FCF. However, the valuation concern is the stock price vs. the analyst target: at $973.36 vs. consensus $894.25, the stock trades 8.8% ABOVE fair value as estimated by the institutional community that just revised estimates upward post-Q3. Near-term EPS growth of 4.1% creates an implied 1-year PEG of 5.2x (21.49/4.1), dramatically overvalued on a 12-month basis. 5-year EPS growth of 20.7% (in line with industry 21.3%) justifies long-term holding for existing positions but does not justify chasing at current levels above analyst target.

News Sentiment

Regeneron Pharmaceuticals is riding one of biotech's biggest earnings waves this quarter, delivering a stunning 70% surge in non-GAAP earnings per share to $20.07 — a number that left Wall Street analysts scrambling to revise their forecasts upward. The headline from 'Regeneron Reports Third Quarter 2026 Financial and Operating Results' tells the story of a company firing on all cylinders: its blockbuster allergy and eczema drug Dupixent continues to dominate the immunology market, while EYLEA HD is holding its ground in eye disease despite biosimilar competition, and cancer drug LIBTAYO is carving out growing market share in oncology. 'These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3' confirms the institutional community is responding to the beat — but crucially, even after raising targets, analysts still see the stock as overvalued at current levels near $973. 'Regeneron: 3 Key Takeaways for Long-Term Investors' and coverage of the Q3 earnings call highlight that the company's pipeline — including weight-loss drug candidates and next-generation antibodies — provides multiple growth avenues beyond its current revenue drivers. The Sanofi collaboration continues generating meaningful partnership revenue. Bottom line for everyday investors: this is a genuinely great company with a spectacular quarter under its belt, but the stock has sprinted ahead of even the upgraded analyst targets, meaning the good news may already be priced in — and then some.

Risk Assessment

PRIMARY RISK: Valuation dislocation above analyst consensus target. At $973.36, the stock has overshot the post-Q3 estimate-revised consensus of $894.25 by 8.8%. This creates a structural mean-reversion risk even if the business continues to perform well — good companies can be bad trades at the wrong price. SECONDARY RISK: Near-term earnings growth deceleration (4.1% next-year EPS growth vs. historical 22.8% YoY) represents a potential consensus disappointment catalyst if near-term results disappoint. TERTIARY RISK: Securities class action lawsuit (Fianlimab melanoma Phase 3 fraud allegations) remains unresolved — no dismissal or settlement in this cycle; unquantifiable liability creates institutional selling pressure. MITIGATION: Stop loss at $865 (11.1% below current, approximately at the analyst target less a 3.3% buffer) limits downside on new entries. Existing holders should maintain positions with stop at ~$920 (prior run-up support). The $9.3B cash fortress means existential risk is essentially zero — this is a quality business that may simply need time to grow into its current price. ENTRY ZONE RATIONALE: $895-$935 represents the zone where the stock begins trading at or below the revised analyst consensus ($894.25), offering a margin of safety relative to current post-earnings euphoria levels.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is REGN a halal stock?

No, Regeneron Pharmaceuticals, Inc. (REGN) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for REGN?

Regeneron Pharmaceuticals, Inc. (REGN) has a Plutrex AI rating of 72.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is REGN a good investment?

According to Plutrex AI, REGN has a Buy rating (72.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in REGN?

US stocks like REGN can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in REGN?

Plutrex AI identifies the main risks for REGN by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about REGN

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open REGN in ElBarake